Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(11 months from now) | |
US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(8 years from now) | |
US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(8 years from now) |
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline
Dosage: TABLET;ORAL
6
United States
4
Japan
3
China
2
Canada
2
Spain
2
Australia
2
Korea, Republic of
2
European Union
1
Hong Kong
1
Slovenia
1
Russia
1
Brazil
1
Portugal
1
Denmark
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic